Osprey Pharmaceuticals Lands $11,000,000 Series A Round

  • Feed Type
  • Date
    9/3/2008
  • Company Name
    Osprey Pharmaceuticals
  • Mailing Address
    425 California Street San Francisco, CA 94104
  • Company Description
    Osprey Pharmaceuticals USA, together with its Montreal, Canada partner, Osprey Pharmaceuticals, Ltd., is developing a series of novel fusion protein therapeutics which selectively target and neutralize activated leukocytes that are implicated in a variety of inflammatory and immune disorders.
  • Website
    http://www.ospreypharma.com/
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $11,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    Proceeds will also be applied to the discovery and development of additional therapeutics that have emerged from the company’s proprietary platform for the discovery of therapeutic Leukocyte Population Modulators (LPMs). LPMs specifically target chemokine-activated leukocytes that drive and/or maintain a variety of inflammatory and autoimmune disorders.
  • M&A Terms
  • Venture Investor
    Burrill & Company
  • Venture Investor
    Novo A/S
  • Venture Investor
    BDC Venture Capital
  • Venture Investor
    GeneChem
  • Venture Investor
    Western Technology Investment

By posting a comment, you agree to our terms and conditions.